CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Incidence, Timing, and Correlates of Stent Thrombosis With the Polymeric Paclitaxel Drug-Eluting StentA TAXUS II, IV, V, and VI Meta-Analysis of 3,445 Patients Followed for Up to 3 Years
Stephen G. Ellis, MD, FACC*,1,2,*,
Antonio Colombo, MD, FACC ,1,
Eberhard Grube, MD, FACC ,1,
Jeffrey Popma, MD, FACC ,1,
Joerg Koglin, MD, FACC||,1,3,
Keith D. Dawkins, MD, FACC¶,2 and
Gregg W. Stone, MD, FACC#,1,2
* The Cleveland Clinic, Cleveland, Ohio
Columbus Hospital, Milan, Italy
Heart Center Siegburg, Siegburg, Germany
Brigham and Women’s Hospital, Boston, Massachusetts
|| Boston Scientific Corporation, Natick, Massachusetts
¶ Southampton University Hospital, Southampton, United Kingdom
# Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York.
Manuscript received July 26, 2006;
revised manuscript received January 2, 2007,
accepted January 9, 2007.
* Reprint requests and correspondence: Dr. Stephen G. Ellis, Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, F25, Cleveland, Ohio 44195. (Email: elliss{at}ccf.org).
Data presented in part at the Transcatheter Cardiovascular Therapeutics Conference, October 23 to 27, 2005, Washington, DC, and the American College of Cardiology Foundation Annual Scientific Session, March 11 to 14, 2006, Atlanta, Georgia.
Objectives: This study sought to study stent thrombosis with the paclitaxel-eluting Taxus stent.
Background: The incidence and timing of stent thrombosis after drug-eluting stent placement compared with bare-metal stent implantation remain unsettled, with consequent uncertainty about risk stratification and long-term recommendations for antiplatelet medications.
Methods: This study used a patient-based meta-analysis using the 4 principal TAXUS randomized trials (3,445 patients) with a follow-up duration of  1 year.
Results: Cumulative stent thrombosis occurred in 1.28% ± 0.31% in the Taxus group and 0.76% ± 0.23% in the bare-metal stent group at 3 years (hazard ratio 1.51 [95% confidence interval 0.73 to 3.14], p = 0.26). Hazard ratios (per 100 patients per 6 months) were similar between the Taxus stent group (0.59 [95% confidence interval 0.22 to 0.95]) and the bare-metal stent group (0.64 [95% confidence interval 0.26 to 1.02]) through 6 months during the prescribed clopidogrel period. However, from 6 months to 3 years there were more stent thromboses in the Taxus group (hazard ratio 0.19 [95% confidence interval 0.06 to 0.32] vs. 0.02 [95% confidence interval 0.00 to 0.07], p = 0.049). Of 8 patients with Taxus-related thrombosis after 6 months, 0 were taking clopidogrel and 2 were not taking aspirin consistently. No Taxus-related stent thrombosis occurred after 2 years (922 patients thus far followed up for 3 years). Independent correlates of stent thrombosis were nonuse of clopidogrel, male gender, smoking, and possibly use of multiple nonoverlapping stents.
Conclusions: Approximately 0.8% of Taxus patients have stent thrombosis in the first 6 months after stent implantation, similar to bare-metal stents. However, a modest increase in risk is present with Taxus stents beyond 6 months, possibly because of inadequate antiplatelet drug therapy.
|
Abbreviations and Acronyms
| | BMS = bare-metal stent | | DES = drug-eluting stent | | MACE = major adverse cardiac event | | TVR = target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
J. P. Chen, D. Hou, L. Pendyala, J. A. Goudevenos, and N. G. Kounis
Drug-Eluting Stent Thrombosis: The Kounis Hypersensitivity-Associated Acute Coronary Syndrome Revisited
J. Am. Coll. Cardiol. Intv.,
July 1, 2009;
2(7):
583 - 593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. K. Pendyala, J. Li, T. Shinke, S. Geva, X. Yin, J. P. Chen, S. B. King III, K. A. Robinson, N. A.F. Chronos, and D. Hou
Endothelium-Dependent Vasomotor Dysfunction in Pig Coronary Arteries With Paclitaxel-Eluting Stents Is Associated With Inflammation and Oxidative Stress
J. Am. Coll. Cardiol. Intv.,
March 1, 2009;
2(3):
253 - 262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Stefanadis and K. Toutouzas
Paclitaxel versus sirolimus the battle is still ongoing.
J. Am. Coll. Cardiol.,
February 24, 2009;
53(8):
665 - 666.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A Ostovan, R. Mollazadeh, J. Kojuri, and M. Mirabadi
Experience with Paclitaxel-Eluting Infinnium Coronary Stents
Asian Cardiovasc Thorac Ann,
December 1, 2008;
16(6):
454 - 458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Chhatriwalla and D. L. Bhatt
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely
Circ Cardiovasc Interv,
December 1, 2008;
1(3):
217 - 225.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Shinke, J. Li, J. P. Chen, L. Pendyala, T. Goodchild, R. Jabara, S. Geva, T. Ueno, N. Chronos, K. Robinson, et al.
High Incidence of Intramural Thrombus After Overlapping Paclitaxel-Eluting Stent Implantation: Angioscopic and Histopathologic Analysis in Porcine Coronary Arteries
Circ Cardiovasc Interv,
August 1, 2008;
1(1):
28 - 35.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. T. Newsome, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Anesth. Analg.,
August 1, 2008;
107(2):
552 - 569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2355 - 2369.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Fishbein, I. Alferiev, M. Bakay, S. J. Stachelek, P. Sobolewski, M. Lai, H. Choi, I. -W. Chen, and R. J. Levy
Local Delivery of Gene Vectors From Bare-Metal Stents by Use of a Biodegradable Synthetic Complex Inhibits In-Stent Restenosis in Rat Carotid Arteries
Circulation,
April 22, 2008;
117(16):
2096 - 2103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol.,
August 14, 2007;
50(7):
e1 - e157.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Bavry and D. L. Bhatt
Drug-Eluting Stents: Dual Antiplatelet Therapy for Every Survivor?
Circulation,
August 14, 2007;
116(7):
696 - 699.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Jaffe and B. H. Strauss
Late and Very Late Thrombosis of Drug-Eluting Stents: Evolving Concepts and Perspectives
J. Am. Coll. Cardiol.,
July 10, 2007;
50(2):
119 - 127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Harrington and E. M. Ohman
The Enigma of Drug-Eluting Stents: Hope, Hype, Humility, and Advancing Patient Care
JAMA,
May 9, 2007;
297(18):
2028 - 2030.
[Full Text]
[PDF]
|
|
|
|
